Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial

PITCH Consortium; Sian Faustini; Andrew Hall; Sarah Brown; Sadie Roberts; Harriet Hill; Zania Stamataki; Matthew W. Jenner; Roger G Owen; Dickens Pratt; Gordon Cook; Alex Richter; Mark Drayson; Martin F Kaiser; Jennifer Heaney

doi:10.1111/bjh.18714

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial

PITCH Consortium
, Sian Faustini
, Andrew Hall
, Sarah Brown
, Sadie Roberts
, Harriet Hill
, Zania Stamataki
, Matthew W. Jenner
, Roger G Owen
, Dickens Pratt
, Gordon Cook
, Alex Richter
, Mark Drayson
, Martin F Kaiser
, Jennifer Heaney^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

82 Downloads (Pure)

Abstract

Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.

Original language	English
Pages (from-to)	845-850
Number of pages	6
Journal	British Journal of Haematology
Volume	201
Issue number	5
Early online date	9 Mar 2023
DOIs	https://doi.org/10.1111/bjh.18714
Publication status	Published - Jun 2023

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

antibodies
anti-CD38
high-dose therapy
multiple myeloma
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
SHORT REPORT
severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
anti‐CD38
SHORT REPORTS
high‐dose therapy

Access to Document

10.1111/bjh.18714Licence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

FaustiniS2023ImmuneFinal published version, 1.28 MBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Cite this

PITCH Consortium, Faustini, S., Hall, A., Brown, S., Roberts, S., Hill, H., Stamataki, Z., Jenner, M. W., Owen, R. G., Pratt, D., Cook, G., Richter, A., Drayson, M., Kaiser, M. F., & Heaney, J. (2023). Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. British Journal of Haematology, 201(5), 845-850. https://doi.org/10.1111/bjh.18714

@article{48f263c405384f189c23929b7035da52,

title = "Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial",

abstract = "Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.",

keywords = "antibodies, anti-CD38, high-dose therapy, multiple myeloma, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), SHORT REPORT, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), anti‐CD38, SHORT REPORTS, high‐dose therapy",

author = "\{PITCH Consortium\} and Sian Faustini and Andrew Hall and Sarah Brown and Sadie Roberts and Harriet Hill and Zania Stamataki and Jenner, \{Matthew W.\} and Owen, \{Roger G\} and Dickens Pratt and Gordon Cook and Alex Richter and Mark Drayson and Kaiser, \{Martin F\} and Jennifer Heaney and Elena Efstathiou",

note = "{\textcopyright} 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley \& Sons Ltd.",

year = "2023",

month = jun,

doi = "10.1111/bjh.18714",

language = "English",

volume = "201",

pages = "845--850",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "5",

}

PITCH Consortium, Faustini, S, Hall, A, Brown, S, Roberts, S, Hill, H, Stamataki, Z, Jenner, MW, Owen, RG, Pratt, D, Cook, G, Richter, A , Drayson, M, Kaiser, MF & Heaney, J 2023, 'Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial', British Journal of Haematology, vol. 201, no. 5, pp. 845-850. https://doi.org/10.1111/bjh.18714

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. / PITCH Consortium ; Faustini, Sian; Hall, Andrew et al.
In: British Journal of Haematology, Vol. 201, No. 5, 06.2023, p. 845-850.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma

T2 - results from the Myeloma UK (MUK) nine OPTIMUM trial

AU - PITCH Consortium

AU - Faustini, Sian

AU - Hall, Andrew

AU - Brown, Sarah

AU - Roberts, Sadie

AU - Hill, Harriet

AU - Stamataki, Zania

AU - Jenner, Matthew W.

AU - Owen, Roger G

AU - Pratt, Dickens

AU - Cook, Gordon

AU - Richter, Alex

AU - Drayson, Mark

AU - Kaiser, Martin F

AU - Heaney, Jennifer

AU - Efstathiou, Elena

PY - 2023/6

Y1 - 2023/6

N2 - Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.

AB - Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.

KW - antibodies

KW - anti-CD38

KW - high-dose therapy

KW - multiple myeloma

KW - severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

KW - SHORT REPORT

KW - severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

KW - anti‐CD38

KW - SHORT REPORTS

KW - high‐dose therapy

UR - https://www.scopus.com/pages/publications/85150653974

U2 - 10.1111/bjh.18714

DO - 10.1111/bjh.18714

M3 - Article

C2 - 36895158

SN - 0007-1048

VL - 201

SP - 845

EP - 850

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this